Celecoxib for the Prevention of Colorectal Adenomatous Polyps

2006975 citationsJournal Articlebronze Open Access

Authors

Nadir Arber · Tel Aviv University

Craig Eagle · Pfizer (United States)

Julius Špičák · Institute of Clinical and Experimental Medicine

I Rácz · Petz Aladár Megyei Oktató Kórház

Petr Dítě · University Hospital Brno

Jan Hajer · University Hospital Kralovske Vinohrady

Miroslav Zavoral

Abstract

The use of 400 mg of celecoxib once daily significantly reduced the occurrence of colorectal adenomas within three years after polypectomy. (ClinicalTrials.gov number, NCT00141193 [ClinicalTrials.gov].).

Topics & Keywords

Inflammatory mediators and NSAID effects Estrogen and related hormone effects Helicobacter pylori-related gastroenterology studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 355, Issue 9, pp. 885-895

DOI: 10.1056/nejmoa061652

Field-Weighted Citation Impact: 74.46